Vertex Pharmaceuticals (NASDAQ:VRTX) is approaching a Nov. 30 U.S. regulatory decision for its kidney disease drug ...
Johnson & Johnson's diversified MedTech and pharma mix faces off against Vertex's cystic fibrosis dominance, but their ...
Analysts are broadly confident that povetacicept will notch an approval in IgA nephropathy by the end of the month, setting ...
Vertex is betting on nephrology and rare endocrinology to build a fifth and fourth commercial pillar beyond cystic fibrosis.
Analyst sees Maze Therapeutics' APOL1 program advancing toward pivotal trials on HORIZON data, with early 2027 catalysts and funding into 2029.
Jeff Leiden says drug discovery is the ultimate team sport, and he built a leadership team that argued its way to better ...
Consulting and expert advisory firm Ankura has sued rival Vertex Companies, accusing it of a campaign to recruit ​key personnel from Ankura units that serve law firms, litigation ‌clients and others.
Vertex Pharmaceuticals earns steady profits from its cystic fibrosis medicines while expanding into new diseases. BioNTech ...
Amgen trades at a lower forward P/E than Vertex, but Vertex's near-zero debt and cystic fibrosis dominance make the trade-off ...